Figure 1.

miR-148a-3p is downregulated during AD progression

(A) miR-148a-3p expression in the cortex of APP/PS1 mice using RNA-sequencing analysis at different stages of AD (n = 3). Two-way hierarchical clustering of miRNAs in sequencing experiments was performed to differentiate miRNAs with differential expression levels at different stages of AD. The color scale indicates the relative expression of an miRNA in a particular age group: red represents high relative expression, and green represents low relative expression. (B) Receiver operating characteristic (ROC) curves discriminate APP/PS1 mice from WT control mice in terms of miR-148a-3p levels from miRNA profiling. (C and D) Decreased expression of miR-148a-3p in the hippocampus (C) and cortex (D) of APP/PS1 mice and SAMP8 mice (n = 4). (E) Decreased expression of miR-148a-3p in APPswe cell lines from 24 to 48 h (n = 5). (F) Reduced levels of miR-148a-3p in the serum of AD patients compared with healthy age-matched volunteers (HAVs) (n = 15–21). (G) Correlation analysis of serum miR-148a-3p levels and MMSE score using Pearson correlation. (H) ROC curves discriminate AD patients from HAVs through serum miR-148a-3p levels (n = 15–21). Results represent means ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 versus corresponding control.